Carl Roth
Internal Medicine · Silver Creek, NYNPI 1942303029
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 233 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,980 and has fallen 67.2% since, to $650 in 2024.
Across 233 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$415
- AbbVie$362
- Lilly USA, LLC$351
- GSK$327
- AstraZeneca$295
- Pfizer$242
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,80297%
- Education$1093%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $415 |
| AbbVie | 20 | $362 |
| Lilly USA, LLC | 24 | $351 |
| GSK | 24 | $327 |
| AstraZeneca | 15 | $295 |
| Pfizer | 15 | $242 |
| Astellas Pharma US Inc | 8 | $227 |
| Amgen | 13 | $202 |
| Bayer | 10 | $198 |
| Merck | 10 | $172 |
| Boehringer Ingelheim | 11 | $171 |
| Otsuka America Pharmaceutical, Inc. | 8 | $146 |
| Sanofi-aventis U.S. LLC | 6 | $102 |
| Sumitomo Pharma America, Inc. | 4 | $100 |
| Exact Sciences | 4 | $98 |
| Johnson & Johnson | 5 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $73 |
| Novartis | 3 | $48 |
| Lundbeck LLC | 2 | $42 |
| Dexcom, Inc. | 2 | $40 |
| Mylan Specialty L.p. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $34 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Edwards Lifesciences | 1 | $21 |
| Advanced Oxygen Therapy Inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Boston Scientific | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
How this compares
$3,911 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 292 | $209,264 |
| JardianceEmpagliflozin | 154 | $165,835 |
| XareltoRivaroxaban | 129 | $106,295 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 146 | $100,732 |
| OzempicSemaglutide | 86 | $87,498 |
| OtezlaApremilast | 29 | $65,381 |
| FarxigaDapagliflozin Propanediol | 43 | $64,660 |
| TrulicityDulaglutide | 30 | $54,715 |
| RexultiBrexpiprazole | 23 | $33,442 |
| MounjaroTirzepatide | 27 | $31,767 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $30,260 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 26 | $27,885 |
| RybelsusSemaglutide | 12 | $19,789 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $10,310 |
| MyrbetriqMirabegron | 37 | $10,298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $242 | $209,264292 claims |
| Boehringer IngelheimJardiance | $171 | $165,835154 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $327 | $136,359214 claims |
| Novo NordiskOzempic, Rybelsus | $415 | $107,28798 claims |
| Johnson & JohnsonXarelto | $91 | $106,295129 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $351 | $86,48257 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $295 | $74,97156 claims |
| AmgenOtezla | $202 | $65,38129 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $146 | $33,44223 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $102 | $27,88526 claims |
| Astellas Pharma US IncMyrbetriq | $227 | $10,29837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Silver Creek
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.